Partnership with Genezen Expanded to Strengthen Support for Foundation-Funded Gene Therapy Programs

We are pleased to announce that we have expanded our collaboration with Genezen, a best-in-class viral vector contract development and manufacturing organization. As part of an initiative designed to help advance viral vector manufacturing for patient-led and foundation-supported programs, we will provide Genezen’s clients with outsourced GMP biosafety and analytical testing services.

These programs, often funded by parents, families, and patient advocacy foundations, represent some of the most urgent and impactful work in gene therapy. By improving and accelerating access to critical analytical and biosafety testing, this collaboration helps remove barriers and enables more programs to advance toward the clinic.

Through this partnership, Genezen clients will gain access to our comprehensive suite of GMP-compliant biosafety and characterization services, spanning early-phase development through clinical and commercial release. Our laboratories in Glasgow (UK) and Lincolnshire (US) provide more than 300 validated assays and support a wide range of modalities, including viral vectors, cell and gene therapies, and vaccines, all performed in accordance with global regulatory standards.

“Foundation-supported programs are some of the most meaningful and time-sensitive initiatives in our industry,” said Susan D’Costa, Genezen’s Chief Technical and Chief Commercial Officer. “By partnering with SGS to streamline access to  critical testing services, we’re helping ensure these programs can move forward with greater speed, efficiency, and confidence.”

“Collaborating with Genezen allows us to support programs that are not only scientifically complex, but deeply meaningful,” said Mike Pipis, MSc, Head of Sales – Biosafety for SGS in North America. “We are proud to provide dedicated, mission-driven support that helps remove barriers and accelerate progress for patients and families.”

“The sense of urgency and commitment to innovation from both the Genezen and SGS teams is palpable,” said Tiffany Sepp, Development Team Leader for The Charlotte and Gwenyth Gray Foundation to Cure Batten Disease, the first organization to benefit from the collaboration. “We all know, we all feel, we all are committed – these kiddos can't wait. And these talented teams share our perspectives on the rare disease families we all work tirelessly to serve. The entire Charlotte and Gwenyth Gray Foundation is left with an impression that will not soon be forgotten.”

As a global leader in biopharmaceutical testing with deep expertise in biologics, we have a proven track record of supporting biopharmaceutical manufacturers from early development through batch release. Our biosafety center features advanced laboratory infrastructure and a team of experienced scientists dedicated to delivering high-quality, reliable results.

Our partnership with Genezen reflects a shared commitment to advancing gene therapy programs that may not follow traditional commercial pathways but are vital to addressing rare and life-threatening diseases. Combining our industry-leading testing capabilities with Genezen’s expertise in viral vector manufacturing enables the delivery of an integrated solution that improves efficiency and  development challenges.

As demand for gene therapies continues to grow, particularly among foundation-backed and early-stage programs, partnerships like this play a critical role in enabling broader access to high-quality manufacturing and testing infrastructure.